Skip to main content
Equibles
GKOS logo

GKOS · GLAUKOS Corp

Track GKOS — free

Use GKOS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GKOS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$179.87 -2.04 (-1.12%) At close · Aug 28
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$10.73B
Shares
58.98M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$179.87 Open$181.10 Day$177.77–182.23 52W close$74.67–189.55 Avg vol 30d810K Short int4.0M · 6.7% float · 5.2d Short vol39% Last earningsJul 29, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Oct 28, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 29, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol High
      Market backdrop VIX 14.4 · calm Equity put/call 0.39
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +41%
      above
      Price vs 50-day avg +11%
      above
      RSI (14) 57
      neutral
      MACD trend Negative
      52-week position 92%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +8%
      trailing
      6-month return +70%
      trailing
      YTD return +59%
      this year
      Relative strength +57%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $162 › 200d $127 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +68 funds added
      Insider flow Distributing
      Net -$11.3M over 90 days · 100% sells
      Short interest Rising
      6.70% of float · ▲ +9.0% MoM · 5.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      364 holders — near 3-yr high, broad support
      Squeeze score 76
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +32%
      Y/Y
      Gross margin 56%
      contracting
      EPS growth −18%
      Y/Y
      Free cash flow $-22.5M
      Balance sheet $11.9M
      net cash
      Quant / Vol
      risk profile
      High
      Volatility 53%
      annualized · 1-yr
      Max drawdown −28%
      past year
      ATR 3.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 3
      Latest guidance · from the 8-K filed Jul 29, 2026
      2026 net sales · 2026 $680M – $700M
      prior FY $507.44M midpoint +36.0% Y/Y
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
      Net sales · full year 2025 $490M – $495M
      Guided vs delivered · last 3 settled
      Full-year 2024 net sales full-year 2024
      guided $350M – $360M
      $383.48M Beat +8.0%
      2023 net sales guidance range 2023
      guided $307M – $310M
      $314.71M Beat +2.0%
      Net sales 2022
      guided $278M – $280M
      $282.86M Beat +1.4%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +41% Bullish
      Price vs 50-day avg
      +11% Bullish
      RSI (14)
      57 Neutral
      MACD trend
      Negative Bearish
      52-week position
      92% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $162 › 200d $127 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +68 funds added
      Insider flow Distributing
      Net -$11.3M over 90 days · 100% sells
      Short interest Rising
      6.70% of float · ▲ +9.0% MoM · 5.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      364 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $75 Now $180 · 92% Range high $190
      vs 200-day avg +41% vs 50-day avg +11%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      International Glaucoma Reported Sales 36.63M Q2 2026 —
      International Glaucoma Year-over-Year Operations Percent Change 16.4% Q2 2026 —
      International Glaucoma Year-over-Year Reported Percent Change 17.2% Q2 2026 —
      non-GAAP Cost of sales non-GAAP 28.74M Q2 2026 —
      Non-GAAP net loss per diluted share non-GAAP -$0.14 the second quarter of 2026 —
      non-GAAP Selling, general and administrative non-GAAP 111.66M Q2 2026 —
      Total Net Sales Year-over-Year Operations Percent Change 49.3% Q2 2026 —
      Cash & Cash Equivalents, Short-Term Investments, and Restricted Cash $280.5M as of March 31, 2026 —
      non-GAAP net loss non-GAAP $10.4M first quarter of 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Net loss -19.78M
      +9.37M Adjustments (including total tax effect for non-GAAP pre-tax adjustments)
      = Non-GAAP Net loss -10.42M

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GKOS
      GLAUKOS Corp
      this stock
      		$10.73B +59.3% +32.3% — 6.7%
      ABT
      Abbott Laboratories
      		 $195.90B -10.2% +5.7% 31.5 1.2%
      SYK
      Stryker Corp
      		 $127.12B -5.9% +11.2% 34.3 1.8%
      MDT
      Medtronic plc
      		 $115.17B -5.0% +8.4% 24.1 1.1%
      BSX
      Boston Scientific Corp
      		 $68.44B -50.9% +12.5% 19.1 1.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      364
      % held
      104.6%
      Net QoQ
      +2.8M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      428
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      4.0M
      Days to cover
      5.2d
      Change
      +324.7K sh
      View
      Short Volume
      Short vol %
      39%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      100
      Value
      $15.2K
      As of
      Jul 24, 2026
      View
      Off-Exchange
      Off-exchange %
      38.2%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$11.3M
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $507.4M
      Net income (FY)
      $-187.7M
      EPS diluted
      $-3.28
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 3, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $2.5M
      Shares
      13.7K
      Filed
      Aug 28, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 9, 2026
      Last call
      Jul 29, 2026
      View
      Investor Relations
      Latest news
      Glaukos Announces Participation i…
      Published
      Aug 19, 2026
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      GKOS -2.7% +7.9% +70.0% +7.9% +59.3%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY -3.2% +4.9% +56.6% +4.9% +46.5%
      Key facts CIK 1192448 CUSIP 377322102 13F (30d) 287 filings 287 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)